Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21469786 | 1.00 | EPHX1 (0.61) | EPHX1CSNK1ESIGMAR1ANPEPSLC6A2 | |
| Hydrochloric Acid SCHEMBL22774302 | 0.98 | EPHX1 (0.59) | EPHX1CSNK1ESIGMAR1ANPEPSLC6A2 | |
| Ammonia Solution, Strong SCHEMBL6615975 | 0.98 | EPHX1 (0.59) | EPHX1CSNK1ESIGMAR1ANPEPSLC6A2 | |
| SCHEMBL3840317 | 0.94 | CSNK1E (0.68) | EPHX1CSNK1ESIGMAR1ANPEPSLC6A2 | |
| SCHEMBL15579942 | 0.94 | CSNK1E (0.68) | EPHX1CSNK1ESIGMAR1ANPEPSLC6A2 | |
| SCHEMBL11455433 | 0.92 | CSNK1E (0.71) | EPHX1CSNK1ESIGMAR1ANPEPSLC6A2 | |
| SCHEMBL873387 | 0.92 | CSNK1E (0.71) | EPHX1CSNK1ESIGMAR1ANPEPSLC6A2 | |
| SCHEMBL10399079 | 0.92 | CSNK1E (0.71) | EPHX1CSNK1ESIGMAR1ANPEPSLC6A2 | |
| SCHEMBL4878177 | 0.92 | CSNK1E (0.71) | EPHX1CSNK1ESIGMAR1ANPEPSLC6A2 | |
| SCHEMBL1829488 | 0.92 | CSNK1E (0.71) | EPHX1CSNK1ESIGMAR1ANPEPSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194969-A1 | METAL HALIDE PEROVSKITE LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2022-06-23 | — | — | US | claimed |
| WO-2020130592-A1 | METAL HALIDE PEROVSKITE LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING SAME | 서울대학교산학협력단 | 2020-06-25 | — | — | WO | claimed |
| US-5264583-A | Photographic coupler and method of making the same | EASTMAN KODAK COMPANY (US) | 1993-11-23 | — | — | US | claimed |
| US-20260053831-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | DIAMOND THERAPEUTICS INC (CA) | 2026-02-26 | — | — | US | disclosed |
| US-20260053829-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | DIAMOND THERAPEUTICS INC (CA) | 2026-02-26 | — | — | US | disclosed |
| US-20250176904-A1 | PRE-DOSING METHOD OF ASSESSING DRUG BENEFITS IN PATIENTS | DIAMOND THERAPEUTICS INC (CA) | 2025-06-05 | — | — | US | disclosed |
| US-20250182901-A1 | SYSTEMS AND METHODS FOR AFFECTING WELL-BEING | DIAMOND THERAPEUTICS INC (CA) | 2025-06-05 | — | — | US | disclosed |
| US-20240120053-A1 | 5-HT RECEPTOR AGONIST TITRATION | DIAMOND THERAPEUTICS INC. (CA) | 2024-04-11 | — | — | US | disclosed |
| US-20230233584-A1 | EXTENDED RELEASE 5-HT RECEPTOR AGONISTS FOR NEUROLOGICAL CONDITIONS | DIAMOND THERAPEUTICS INC. (CA) | 2023-07-27 | — | — | US | disclosed |
| US-20220194969-A1 | METAL HALIDE PEROVSKITE LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2022-06-23 | — | — | US | disclosed |
| US-20220194969-A1 | METAL HALIDE PEROVSKITE LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2022-06-23 | — | — | US | disclosed |
| US-6147084-A | Brain cell protective agent | TORAY INDUSTRIES, INC. (JP) | 2000-11-14 | — | — | US | disclosed |
| US-5972953-A | MORPHINAN DERIVATIVE; USEFAL AS PREVENTIVE AND THERAPUETIC AGENTS OF ISCHEMIC BRAIN DISORDERS, BRAIN NERVE CELL DISORDERS AND DEMENTIA | TORAY INDUSTRIES, LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0661283-B1 | BRAIN CELL PROTECTIVE | TORAY INDUSTRIES (JP) | 1998-10-21 | — | — | EP | disclosed |
| EP-0661283-A1 | BRAIN CELL PROTECTIVE | TORAY INDUSTRIES, INC. (JP) | 1995-07-05 | — | — | EP | disclosed |
| US-5292743-A | Substituted guanidines; low phytotoxicity; agricultural use | DOWELANCO (US) | 1994-03-08 | — | — | US | disclosed |
| EP-0576089-A2 | Photographic material and process comprising a coupler capable of forming a wash-out dye | EASTMAN KODAK COMPANY (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5264583-A | Photographic coupler and method of making the same | EASTMAN KODAK COMPANY (US) | 1993-11-23 | — | — | US | disclosed |
| WO-1991005473-A1 | FUNGICIDAL COMPOSITIONS, FUNGICIDAL COMPOUNDS, THEIR PRODUCTION AND USE | DOW CHEMICAL COMPANY LIMITED (GB) | 1991-05-02 | — | — | WO | disclosed |
| EP-0344425-A2 | N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents | WARNER-LAMBERT COMPANY (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194969-A1 | METAL HALIDE PEROVSKITE LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING SAME | HCN4, SLC46A1, FES | EPHX1 3025/4885CSNK1E 4602/4885SIGMAR1 4641/4885 |
| US-20260053829-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | HTR1A, HTR5A, HTR3B | EPHX1 915/4885CSNK1E 3047/4885SIGMAR1 290/4885 |
| US-20250176904-A1 | PRE-DOSING METHOD OF ASSESSING DRUG BENEFITS IN PATIENTS | HTR1A, HTR3A, HTR2B | EPHX1 1341/4885CSNK1E 3204/4885SIGMAR1 117/4885 |
| US-20230233584-A1 | EXTENDED RELEASE 5-HT RECEPTOR AGONISTS FOR NEUROLOGICAL CONDITIONS | HTR1A, HTR2A, HTR5A | EPHX1 598/4885CSNK1E 2375/4885SIGMAR1 174/4885 |
| US-20240120053-A1 | 5-HT RECEPTOR AGONIST TITRATION | HTR1A, HTR3A, HTR5A | EPHX1 1429/4885CSNK1E 2411/4885SIGMAR1 189/4885 |
| US-20260053831-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | HTR1B, HTR2B, HTR3B | EPHX1 2286/4885CSNK1E 1246/4885SIGMAR1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.